U.S. FDA Approves Cemiplimab to Treat cSCC With High Risk of Recurrence After Surgery and Radiation
The U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (cSCC) at high risk of recurrence after surgery and radiation.